Insider Purchases: Inside the Buy

Tag: specialty insurance

Everest Group investor snapshot—director buys near $306–$307, $1.2B adverse development cover, AIG renewal-rights sale, catastrophe-risk radar, and ~1.0x P/B valuation.

Two Directors Bought Shares of Everest Group (EG) Cheaper Than the CEO Did 6 Months Ago: Will Buying Now Culminate in Profits?

Two Everest Group directors just bought stock around $306–$307—below the CEO’s June buy—while the company cleans house with a $1.2B adverse development cover and a renewal-rights sale to AIG. Institutions own essentially all the float, short interest is low, and forward P/E looks cheap. Here’s the risk/reward.

Read entire article

Tags: Adverse Development Cover, AIG, Bermuda, Buy Everest Group Stock Or Not, Catastrophe Risk, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, DIrector Buying, Director Insider Buying, Dividend, Dividends & Buybacks, EG, Everest Group, Funanc1al edge, Funanc1al humor, Funanc1al Investing, Insider Purchases, Institutional Ownership, Insurance, Reinsurance, Risk Management, Specialty Insurance, Valuation
Playful digital illustration of Ryan Specialty’s executive chairman standing confidently on a skyscraper-sized insurance policy with a cash briefcase, as Wall Street skyline and insurance icons highlight insider buying and institutional support.

Executive Chairman Adds To His Already Huge Stake in Ryan Specialty Holdings. Should You Follow His Lead?

Executive Chairman Patrick Ryan just added $14M to his already massive stake in Ryan Specialty Holdings. With strong revenue growth and heavy institutional backing, is this insurance play worth your portfolio — or is it still too pricey?

 

Read entire article

Tags: Chairman buying, COB insider buy, Funanc1al Edge, Funanc1al Humor, Funanc1al Investing, Growth Investing, growth stocks, insider buying, institutional investors, insurance stocks, investing 2025, Patrick Ryan, RYAN, Ryan Specialty, specialty insurance